Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
NX
NextCure, Inc. Common Stock
NXTC
Mkt Cap
$28.7M
Volume
38.84K
Next Earnings
November 4th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
NX
NXTC
NX
NextCure, Inc. Common Stock
NXTC
News
·
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders
Mkt Cap
$28.6M
Volume
38.84K
Next Earnings
November 4th
Chart
Financials
Earnings
News
About
Insider
Filings
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders
Law firm Halper Sadeh LLC is investigating whether NextCure, Inc. obtained a fair price in its proposed merger with Avere Therapeutics, where NextCure shareholders would own only approximately 1.21% of the combined company. The investigation examines potential violations of federal securities laws and breaches of fiduciary duty regarding fair pricing, sales process integrity, and disclosure adequacy.
GlobeNewswire Inc. · Jul 14, 2026
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
NextCure Inc. announced a definitive merger agreement with privately-held Avere Therapeutics in an all-stock transaction. The combined company will operate as Avere Therapeutics and trade on Nasdaq under ticker 'AVRX'. Avere's lead program AVR-001, an oral IL-23 receptor antagonist, received $320 million in concurrent private investment. The merger is expected to close in H2 2026, with NextCure stockholders owning approximately 1.21% of the combined entity.
GlobeNewswire Inc. · Jul 14, 2026
What's Going On With NextCure Stock Wednesday?
NextCure (NASDAQ: NXTC) shares rose 2.10% in premarket trading Wednesday following positive Phase 1 clinical data for SIM0505, an antibody-drug conjugate developed with Simcere Zaiming Pharmaceutical for treating platinum-resistant ovarian cancer and uterine serous carcinoma. However, the stock remains deeply oversold with technical indicators showing a bearish trend despite the positive catalyst.
Benzinga · Jun 3, 2026
NextCure Provides Business Update
NextCure announced Phase 1 dose escalation data for SIM0505 (CDH6 ADC) expected in Q2 2026 and expanded higher dose cohorts for LNCB74 (B7-H4 ADC). The company reported preliminary year-end 2025 cash position of $41.8 million and expects resources to fund operations into the first half of 2027. LNCB74 proof-of-concept data timeline was delayed to second half of 2026 to accommodate enrollment.
GlobeNewswire Inc. · Jan 23, 2026
NextCure (NXTC) Q2 Loss Widens 71%
NextCure reported a Q2 2025 net loss of $26.8 million, primarily due to a $17.0 million license fee for SIM0505. The company advanced its lead clinical programs LNCB74 and SIM0505, with proof-of-concept data expected in the first half of 2026.
The Motley Fool · Aug 8, 2025
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
NextCure, a clinical-stage biopharmaceutical company, announced the completion of cohort 1 of the Phase 1 trial for its B7-H4 ADC drug candidate and plans to initiate backfill cohorts in the second half of 2025. The company reported a cash position of approximately $68.6 million.
GlobeNewswire Inc. · Apr 4, 2025
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
NextCure, a clinical-stage biopharmaceutical company, announced its participation in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on December 5, 2024.
GlobeNewswire Inc. · Nov 26, 2024
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024.
GlobeNewswire Inc. · Jun 20, 2024
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
NextCure, Inc. (Nasdaq: NXTC) will present phase 1b data of NC410 in combination with pembrolizumab at ASCO 2024.
GlobeNewswire Inc. · Apr 24, 2024
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74 Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74
GlobeNewswire Inc. · Apr 8, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
NX
NXTC
NextCure, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
NXTC
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any NXTC yet.
Related Tickers
Earnings